{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:31:55Z","timestamp":1787225515794,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI141390"],"award-info":[{"award-number":["AI141390"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCLA AIDS Institute and Charity Treks"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To generate an inexpensive readily manufactured COVID-19 vaccine, we employed the LVS \u0394\n                    <jats:italic>capB<\/jats:italic>\n                    vector platform, previously used to generate potent candidate vaccines against Select Agent diseases tularemia, anthrax, plague, and melioidosis. Vaccines expressing SARS-CoV-2 structural proteins are constructed using the LVS \u0394\n                    <jats:italic>capB<\/jats:italic>\n                    vector, a highly attenuated replicating intracellular bacterium, and evaluated for efficacy in golden Syrian hamsters, which develop severe COVID-19-like disease. Hamsters immunized intradermally or intranasally with a vaccine co-expressing the Membrane and Nucleocapsid proteins and challenged 5 weeks later with a high dose of SARS-CoV-2 are protected against severe weight loss and lung pathology and show reduced viral loads in the oropharynx and lungs. Protection correlates with anti-Nucleocapsid antibody. This potent vaccine should be safe; inexpensive; easily manufactured, stored, and distributed; and given the high homology between Membrane and Nucleocapsid proteins of SARS-CoV and SARS-CoV-2, potentially serve as a universal vaccine against the SARS subset of pandemic causing \u03b2-coronaviruses.\n                  <\/jats:p>","DOI":"10.1038\/s41541-021-00321-8","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T06:03:17Z","timestamp":1617084197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2328-4806","authenticated-orcid":false,"given":"Qingmei","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-5445","authenticated-orcid":false,"given":"Helle","family":"Bielefeldt-Ohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4003-2643","authenticated-orcid":false,"given":"Rachel M.","family":"Maison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-6670","authenticated-orcid":false,"given":"Sa\u0161a","family":"Masle\u0161a-Gali\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9656-2283","authenticated-orcid":false,"given":"Sarah K.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-7147","authenticated-orcid":false,"given":"Marcus A.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"321_CR1","unstructured":"Center, J. H. C. R. https:\/\/coronavirus.jhu.edu\/map.html (2020)."},{"key":"321_CR2","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1016\/j.vaccine.2016.08.041","volume":"34","author":"Q Jia","year":"2016","unstructured":"Jia, Q. et al. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge. Vaccine 34, 4969\u20134978 (2016).","journal-title":"Vaccine"},{"key":"321_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24581-y","volume":"8","author":"Q Jia","year":"2018","unstructured":"Jia, Q. et al. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci. Rep. 8, 7009 (2018).","journal-title":"Sci. Rep."},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1586\/14760584.3.3.307","volume":"3","author":"JW Conlan","year":"2004","unstructured":"Conlan, J. W. Vaccines against Francisella tularensis\u2014past, present and future. Expert Rev. Vaccine 3, 307\u2013314 (2004).","journal-title":"Expert Rev. Vaccine"},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1016\/j.vaccine.2017.07.024","volume":"35","author":"MJ Mulligan","year":"2017","unstructured":"Mulligan, M. J. et al. Tularemia vaccine: Safety, reactogenicity, \u201cTake\u201d skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain\u2014A phase 2 randomized clinical Trial. Vaccine 35, 4730\u20134737 (2017).","journal-title":"Vaccine"},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cell.2015.02.005","volume":"160","author":"DL Clemens","year":"2015","unstructured":"Clemens, D. L., Ge, P., Lee, B. Y., Horwitz, M. A. & Zhou, Z. H. Atomic structure of T6SS reveals interlaced array essential to function. Cell 160, 940\u2013951 (2015).","journal-title":"Cell"},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1128\/IAI.72.6.3204-3217.2004","volume":"72","author":"DL Clemens","year":"2004","unstructured":"Clemens, D. L., Lee, B. Y. & Horwitz, M. A. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect. Immun. 72, 3204\u20133217 (2004).","journal-title":"Infect. Immun."},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1128\/IAI.73.9.5892-5902.2005","volume":"73","author":"DL Clemens","year":"2005","unstructured":"Clemens, D. L., Lee, B. Y. & Horwitz, M. A. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect. Immun. 73, 5892\u20135902 (2005).","journal-title":"Infect. Immun."},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1128\/IAI.00192-10","volume":"78","author":"Q Jia","year":"2010","unstructured":"Jia, Q. et al. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge. Infect. Immun. 78, 4341\u20134355 (2010).","journal-title":"Infect. Immun."},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"321_CR11","doi-asserted-by":"publisher","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94 https:\/\/doi.org\/10.1128\/JVI.00127-20 (2020).","DOI":"10.1128\/JVI.00127-20"},{"key":"321_CR12","first-page":"2428","volume":"71","author":"JF Chan","year":"2020","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"321_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292 (2020).","journal-title":"Cell"},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1126\/science.abc4262","volume":"368","author":"K Chumakov","year":"2020","unstructured":"Chumakov, K., Benn, C. S., Aaby, P., Kottilil, S. & Gallo, R. Can existing live vaccines prevent COVID-19? Science 368, 1187\u20131188 (2020).","journal-title":"Science"},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(20)31025-4","volume":"395","author":"N Curtis","year":"2020","unstructured":"Curtis, N., Sparrow, A., Ghebreyesus, T. A. & Netea, M. G. Considering BCG vaccination to reduce the impact of COVID-19. Lancet 395, 1545\u20131546 (2020).","journal-title":"Lancet"},{"key":"321_CR16","doi-asserted-by":"publisher","first-page":"17720","DOI":"10.1073\/pnas.2008410117","volume":"117","author":"LE Escobar","year":"2020","unstructured":"Escobar, L. E., Molina-Cruz, A. & Barillas-Mury, C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc. Natl Acad. Sci. USA 117, 17720\u201317726 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"321_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75491-x","volume":"10","author":"J Hensel","year":"2020","unstructured":"Hensel, J. et al. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci. Rep. 10, 18377 (2020).","journal-title":"Sci. Rep."},{"key":"321_CR18","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2018975117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"321_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","volume":"27","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe 27, 671\u2013680.e672 (2020).","journal-title":"Cell Host Microbe"},{"key":"321_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"321_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578\u2013582 (2020).","journal-title":"Nature"},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.abc6284","volume":"369","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 369, 806\u2013811 (2020).","journal-title":"Science"},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"321_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","volume":"586","author":"NB Mercado","year":"2020","unstructured":"Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583\u2013588 (2020).","journal-title":"Nature"},{"key":"321_CR25","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"321_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18077-5","volume":"11","author":"L Feng","year":"2020","unstructured":"Feng, L. et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat. Commun. 11, 4207 (2020).","journal-title":"Nat. Commun."},{"key":"321_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00279-z","volume":"6","author":"RL Brocato","year":"2021","unstructured":"Brocato, R. L. et al. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters. NPJ Vac. 6, 16 (2021).","journal-title":"NPJ Vac."},{"key":"321_CR28","doi-asserted-by":"crossref","unstructured":"Dormitzer, P. R., Mandl, C. W. & Rappuoli, R. Replicating Vaccines (Springer Basel AG, 2011).","DOI":"10.1007\/978-3-0346-0277-8"},{"key":"321_CR29","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1016\/j.vaccine.2007.02.014","volume":"25","author":"R KuoLee","year":"2007","unstructured":"KuoLee, R., Harris, G., Conlan, J. W. & Chen, W. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25, 3781\u20133791 (2007).","journal-title":"Vaccine"},{"key":"321_CR30","first-page":"11","volume":"6","author":"RB Hornick","year":"1966","unstructured":"Hornick, R. B., Dawkins, A. T., Eigelsbach, H. T. & Tulis, J. J. Oral tularemia vaccine in man. Antimicrob. Agents Chemother. 6, 11\u201314 (1966).","journal-title":"Antimicrob. Agents Chemother."},{"key":"321_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3181\/00379727-132-34331","volume":"132","author":"JJ Tulis","year":"1969","unstructured":"Tulis, J. J., Eigelsbach, H. T. & Hornick, R. B. Oral vaccination against tularemia in the monkeys. Proc. Soc. Exp. Biol. Med. 132, 893\u2013897 (1969).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"321_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1128\/CVI.00405-08","volume":"16","author":"HJ Ray","year":"2009","unstructured":"Ray, H. J. et al. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4(+) T cells and antibodies, including immunoglobulin A. Clin. Vaccine Immunol. 16, 444\u2013452 (2009).","journal-title":"Clin. Vaccine Immunol."},{"key":"321_CR33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/archinte.1961.03620050068007","volume":"107","author":"S Saslaw","year":"1961","unstructured":"Saslaw, S., Eigelsbach, H. T., Prior, J. A., Wilson, H. E. & Carhart, S. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107, 702\u2013714 (1961).","journal-title":"Arch. Intern. Med."},{"key":"321_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/BR.30.3.532-538.1966","volume":"30","author":"RB Hornick","year":"1966","unstructured":"Hornick, R. B. & Eigelsbach, H. T. Aerogenic immunization of man with live Tularemia vaccine. Bacteriol. Rev. 30, 532\u2013538 (1966).","journal-title":"Bacteriol. Rev."},{"key":"321_CR35","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.vaccine.2009.06.036","volume":"27","author":"HM El Sahly","year":"2009","unstructured":"El Sahly, H. M. et al. Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine 27, 4905\u20134911 (2009).","journal-title":"Vaccine"},{"key":"321_CR36","unstructured":"Eigelsbach HT., H. R. in Occupational tularemia Vol. 124, 285\u2013302 (Univ. of Michigan Continued Education, 1962)."},{"key":"321_CR37","unstructured":"Command, U. S. A. M. R. a. D. Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00584844 (2008)."},{"key":"321_CR38","unstructured":"Command, U. S. A. M. R. a. D. Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00787826 (2008)."},{"key":"321_CR39","unstructured":"(NIAID), N. I. o. A. a. I. D. Phase II Tularemia Vaccine Comparison, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01150695 (2010)."},{"key":"321_CR40","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1128\/IAI.00196-09","volume":"77","author":"E Salomonsson","year":"2009","unstructured":"Salomonsson, E. et al. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect. Immun. 77, 3424\u20133431 (2009).","journal-title":"Infect. Immun."},{"key":"321_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1196\/annals.1409.012","volume":"1105","author":"J Wayne Conlan","year":"2007","unstructured":"Wayne Conlan, J. & Oyston, P. C. Vaccines against Francisella tularensis. Ann. N. Y. Acad. Sci. 1105, 325\u2013350 (2007).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"321_CR42","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1586\/erv.09.43","volume":"8","author":"RL Roper","year":"2009","unstructured":"Roper, R. L. & Rehm, K. E. SARS vaccines: where are we? Expert Rev. Vaccines 8, 887\u2013898 (2009).","journal-title":"Expert Rev. Vaccines"},{"key":"321_CR43","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1099\/vir.0.2008\/001891-0","volume":"89","author":"RH See","year":"2008","unstructured":"See, R. H. et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. J. Gen. Virol. 89, 2136\u20132146 (2008).","journal-title":"J. Gen. Virol."},{"key":"321_CR44","doi-asserted-by":"publisher","first-page":"e1000636","DOI":"10.1371\/journal.ppat.1000636","volume":"5","author":"J Zhao","year":"2009","unstructured":"Zhao, J., Zhao, J., Van Rooijen, N. & Perlman, S. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice. PLoS Pathog. 5, e1000636 (2009).","journal-title":"PLoS Pathog."},{"key":"321_CR45","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1128\/JVI.80.8.4079-4087.2006","volume":"80","author":"JS Lee","year":"2006","unstructured":"Lee, J. S. et al. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 80, 4079\u20134087 (2006).","journal-title":"J. Virol."},{"key":"321_CR46","doi-asserted-by":"publisher","first-page":"26382","DOI":"10.1073\/pnas.2013102117","volume":"117","author":"AM Bosco-Lauth","year":"2020","unstructured":"Bosco-Lauth, A. M. et al. Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proc. Natl Acad. Sci. USA 117, 26382\u201326388 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"321_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.mimet.2015.11.018","volume":"121","author":"S Becker","year":"2016","unstructured":"Becker, S., Lochau, P., Jacob, D., Heuner, K. & Grunow, R. Successful re-evaluation of broth medium T for growth of Francisella tularensis ssp. and other highly pathogenic bacteria. J. Microbiol. Methods 121, 5\u20137 (2016).","journal-title":"J. Microbiol. Methods"},{"key":"321_CR48","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"321_CR49","doi-asserted-by":"publisher","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","volume":"114","author":"J Pallesen","year":"2017","unstructured":"Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl Acad. Sci. USA 114, E7348\u2013E7357 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"321_CR50","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1099\/mic.0.022491-0","volume":"155","author":"ED LoVullo","year":"2009","unstructured":"LoVullo, E. D., Molins-Schneekloth, C. R., Schweizer, H. P. & Pavelka, M. S. Single-copy chromosomal integration systems for Francisella tularensis. Microbiology 155, 1152\u20131163 (2009).","journal-title":"Microbiology"},{"key":"321_CR51","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.vaccine.2008.12.014","volume":"27","author":"Q Jia","year":"2009","unstructured":"Jia, Q., Lee, B. Y., Clemens, D. L., Bowen, R. A. & Horwitz, M. A. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis. Vaccine 27, 1216\u20131229 (2009).","journal-title":"Vaccine"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00321-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00321-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T18:30:44Z","timestamp":1670005844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00321-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00321-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.17.387555","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests except M.A.H. and Q.J. are inventors on patent applications filed by UCLA that include data presented herein.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}